B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS

• NWCJ van de Donk,
• M Delforge,
• M Agha,
• AD Cohen,
• YC Cohen,
• J Hillengass,
• S Anguille,
• T Kerre,
• W Roeloffzen,
• JM Schecter,
• KC De Braganca,
• H Varsos,
• L Wang,
• M Vogel,
• E Zudaire,
• C Corsale,
• M Akram,
• D Geng,
• T Nesheiwat,
• L Pacaud,
• P Sonneveld,
• S Zweegman

Affiliations

NWCJ van de Donk

1 Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam (NL)

M Delforge

2 University Hospitals (UZ) Leuven, Leuven (BE)

M Agha

3 UPMC Hillman Cancer Center, Pittsburgh (USA)

AD Cohen

4 Abramson Cancer Center, University of Pennsylvania, Philadelphia (USA)

YC Cohen

5 Tel-Aviv Sourasky (Ichilov) Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel Aviv (IL)

J Hillengass

6 Roswell Park Comprehensive Cancer Center, Buffalo (USA)

S Anguille

7 Vaccine and Infectious Disease Institute, University of Antwerp, Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem (BE)

T Kerre

8 University Hospital Ghent, Ghent (BE)

W Roeloffzen

9 University Medical Center Groningen, Groningen (NL)

JM Schecter

10 Janssen R&D, Raritan (USA)

KC De Braganca

10 Janssen R&D, Raritan (USA)

H Varsos

10 Janssen R&D, Raritan (USA)

L Wang

10 Janssen R&D, Raritan (USA)

M Vogel

11 Janssen Global Services, LLC, Raritan (USA)

E Zudaire

12 Janssen R&D, Spring House (USA)

C Corsale

10 Janssen R&D, Raritan (USA)

M Akram

13 Legend Biotech USA, Piscataway (USA)

D Geng

13 Legend Biotech USA, Piscataway (USA)

T Nesheiwat

13 Legend Biotech USA, Piscataway (USA)

L Pacaud

13 Legend Biotech USA, Piscataway (USA)

P Sonneveld

14 Erasmus MC University and Medical Center, Rotterdam (NL)

S Zweegman

1 Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam (NL)